<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>04260595531297</udiDi>
    <basicUdiDi>B-04260595531297</basicUdiDi>
    <tradeName>Bepanthene® Gotas Oftálmicas</tradeName>
    <deviceName>Sodium Hyaluronate 0.15% - Dexpanthenol Eye Drops</deviceName>
    <manufacturerName>Penta Arzneimittel GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000006565</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>41087600L</reference>
    <placedOnMarketCountry>Portugal</placedOnMarketCountry>
    <lastUpdated>2026-07-06T04:53:23.449Z</lastUpdated>
  </row>
  <row>
    <udiDi>03700288631121</udiDi>
    <basicUdiDi>B-03700288631121</basicUdiDi>
    <tradeName>IXIUM NAHA 2%</tradeName>
    <deviceName>IXIUM NAHA 2% Boite de 20</deviceName>
    <manufacturerName>LABORATOIRE DE CONTACTOLOGIE APPLIQUEE - LCA</manufacturerName>
    <manufacturerSrn>FR-MF-000001732</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>211-0200</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-05T14:47:41.899Z</lastUpdated>
  </row>
  <row>
    <udiDi>03700288631114</udiDi>
    <basicUdiDi>B-03700288631114</basicUdiDi>
    <tradeName>IXIUM NAHA 1,5%</tradeName>
    <deviceName>IXIUM NAHA 1,5% Boite de 20</deviceName>
    <manufacturerName>LABORATOIRE DE CONTACTOLOGIE APPLIQUEE - LCA</manufacturerName>
    <manufacturerSrn>FR-MF-000001732</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>210-0200</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-05T14:47:25.717Z</lastUpdated>
  </row>
  <row>
    <udiDi>03700288631084</udiDi>
    <basicUdiDi>B-03700288631084</basicUdiDi>
    <tradeName>IXIUM TWIN</tradeName>
    <deviceName>IXIUM TWIN Boite de 20</deviceName>
    <manufacturerName>LABORATOIRE DE CONTACTOLOGIE APPLIQUEE - LCA</manufacturerName>
    <manufacturerSrn>FR-MF-000001732</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>212-2200</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-05T14:47:21.731Z</lastUpdated>
  </row>
  <row>
    <udiDi>03700288631077</udiDi>
    <basicUdiDi>B-03700288631077</basicUdiDi>
    <tradeName>IXIUM TWIN</tradeName>
    <deviceName>IXIUM TWIN Boite de 1</deviceName>
    <manufacturerName>LABORATOIRE DE CONTACTOLOGIE APPLIQUEE - LCA</manufacturerName>
    <manufacturerSrn>FR-MF-000001732</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>212-2010</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-05T14:47:20.927Z</lastUpdated>
  </row>
  <row>
    <udiDi>03700288631060</udiDi>
    <basicUdiDi>B-03700288631060</basicUdiDi>
    <tradeName>IXIUM NAHA 2%</tradeName>
    <deviceName>IXIUM NAHA 2% Boite de 1</deviceName>
    <manufacturerName>LABORATOIRE DE CONTACTOLOGIE APPLIQUEE - LCA</manufacturerName>
    <manufacturerSrn>FR-MF-000001732</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>211-0010</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-05T14:47:20.205Z</lastUpdated>
  </row>
  <row>
    <udiDi>03700288631053</udiDi>
    <basicUdiDi>B-03700288631053</basicUdiDi>
    <tradeName>IXIUM NAHA 1,5%</tradeName>
    <deviceName>IXIUM NAHA 1,5% Boite de 1</deviceName>
    <manufacturerName>LABORATOIRE DE CONTACTOLOGIE APPLIQUEE - LCA</manufacturerName>
    <manufacturerSrn>FR-MF-000001732</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>210-0010</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-05T14:47:18.496Z</lastUpdated>
  </row>
  <row>
    <udiDi>03700288631039</udiDi>
    <basicUdiDi>B-03700288631039</basicUdiDi>
    <tradeName>IXIUM HCS</tradeName>
    <deviceName>IXIUM HCS Boite de 1</deviceName>
    <manufacturerName>LABORATOIRE DE CONTACTOLOGIE APPLIQUEE - LCA</manufacturerName>
    <manufacturerSrn>FR-MF-000001732</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>214-0000</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-05T14:47:14.506Z</lastUpdated>
  </row>
  <row>
    <udiDi>03700288631015</udiDi>
    <basicUdiDi>B-03700288631015</basicUdiDi>
    <tradeName>IXIUM HCS</tradeName>
    <deviceName>IXIUM HCS Boite de 20</deviceName>
    <manufacturerName>LABORATOIRE DE CONTACTOLOGIE APPLIQUEE - LCA</manufacturerName>
    <manufacturerSrn>FR-MF-000001732</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>214-0200</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-05T14:47:13.708Z</lastUpdated>
  </row>
  <row>
    <udiDi>08027864012002</udiDi>
    <basicUdiDi>890609220HAOSGV</basicUdiDi>
    <tradeName>08027864012002</tradeName>
    <deviceName>Sodium Hyaluronate Ophthalmic Solutions</deviceName>
    <manufacturerName>BIO-TECH VISION CARE PVT. LTD.</manufacturerName>
    <manufacturerSrn>IN-MF-000008482</manufacturerSrn>
    <authorisedRepresentativeName>Biotech Europe Meditech Inc Limited</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>IE-AR-000004696</authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>VISCOTECH 1%</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-03T18:42:38.989Z</lastUpdated>
  </row>
  <row>
    <udiDi>08682276255319</udiDi>
    <basicUdiDi>8682276255A-5000UW</basicUdiDi>
    <tradeName>KERA</tradeName>
    <deviceName>ACID</deviceName>
    <manufacturerName>HUZUR DENTAL TIBBİ ÜRÜNLER SANAYİ VE TİCARET LİMİTED ŞİRKETİ</manufacturerName>
    <manufacturerSrn>TR-MF-000019287</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf I</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>A-5000</reference>
    <placedOnMarketCountry>Türkiye</placedOnMarketCountry>
    <lastUpdated>2026-07-03T14:43:35.478Z</lastUpdated>
  </row>
  <row>
    <udiDi>08437009065068</udiDi>
    <basicUdiDi>8437009065001030018R</basicUdiDi>
    <tradeName>Sanavita Collirio +day Monodose 10 x 0.4 mL</tradeName>
    <deviceName>Wetting Solution</deviceName>
    <manufacturerName>Unolab manufacturing, S.L.</manufacturerName>
    <manufacturerSrn>ES-MF-000000272</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PSU-0013</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-03T12:02:38.847Z</lastUpdated>
  </row>
  <row>
    <udiDi>08057018170395</udiDi>
    <basicUdiDi>805701817S15VAK</basicUdiDi>
    <tradeName>Viscorib 1.5</tradeName>
    <deviceName>soluzione oftalmica</deviceName>
    <manufacturerName>IROMED GROUP S.R.L.</manufacturerName>
    <manufacturerSrn>IT-MF-000031267</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>S15V003V</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-03T08:25:41.732Z</lastUpdated>
  </row>
  <row>
    <udiDi>08057018170388</udiDi>
    <basicUdiDi>805701817S10VA4</basicUdiDi>
    <tradeName>Viscorib 1.0</tradeName>
    <deviceName>Viscorib 1.0</deviceName>
    <manufacturerName>IROMED GROUP S.R.L.</manufacturerName>
    <manufacturerSrn>IT-MF-000031267</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>S10V003V</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-03T08:25:40.913Z</lastUpdated>
  </row>
  <row>
    <udiDi>08034135271839</udiDi>
    <basicUdiDi>803413527TD029PHTHLMCSLJB</basicUdiDi>
    <tradeName>Droptiva Plus</tradeName>
    <deviceName></deviceName>
    <manufacturerName>NTC Srl</manufacturerName>
    <manufacturerSrn>IT-MF-000026977</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>CMC043</reference>
    <placedOnMarketCountry>Poland</placedOnMarketCountry>
    <lastUpdated>2026-07-03T05:26:47.571Z</lastUpdated>
  </row>
  <row>
    <udiDi>03857500055392</udiDi>
    <basicUdiDi>803413527TD066HYPRTNCPHU7</basicUdiDi>
    <tradeName>Proluxx Edenight</tradeName>
    <deviceName></deviceName>
    <manufacturerName>NTC Srl</manufacturerName>
    <manufacturerSrn>IT-MF-000026977</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>HAO071</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-03T05:18:36.465Z</lastUpdated>
  </row>
  <row>
    <udiDi>03857500055347</udiDi>
    <basicUdiDi>803413527TD067STNCPHTHLSC</basicUdiDi>
    <tradeName>Proluxx Night</tradeName>
    <deviceName></deviceName>
    <manufacturerName>NTC Srl</manufacturerName>
    <manufacturerSrn>IT-MF-000026977</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>HAO058</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-03T05:18:35.665Z</lastUpdated>
  </row>
  <row>
    <udiDi>08906092200187</udiDi>
    <basicUdiDi>890609220HAOSGV</basicUdiDi>
    <tradeName>08906092200187</tradeName>
    <deviceName></deviceName>
    <manufacturerName>BIO-TECH VISION CARE PVT. LTD.</manufacturerName>
    <manufacturerSrn>IN-MF-000008482</manufacturerSrn>
    <authorisedRepresentativeName>Biotech Europe Meditech Inc Limited</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>IE-AR-000004696</authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>BIO-HYALUR</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-02T19:43:52.405Z</lastUpdated>
  </row>
  <row>
    <udiDi>08906092200170</udiDi>
    <basicUdiDi>890609220HAOSGV</basicUdiDi>
    <tradeName>08906092200170</tradeName>
    <deviceName></deviceName>
    <manufacturerName>BIO-TECH VISION CARE PVT. LTD.</manufacturerName>
    <manufacturerSrn>IN-MF-000008482</manufacturerSrn>
    <authorisedRepresentativeName>Biotech Europe Meditech Inc Limited</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>IE-AR-000004696</authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>BIO-HYALUR PLUS</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-02T19:43:35.105Z</lastUpdated>
  </row>
  <row>
    <udiDi>08906092200071</udiDi>
    <basicUdiDi>890609220HAOSGV</basicUdiDi>
    <tradeName>08906092200071</tradeName>
    <deviceName></deviceName>
    <manufacturerName>BIO-TECH VISION CARE PVT. LTD.</manufacturerName>
    <manufacturerSrn>IN-MF-000008482</manufacturerSrn>
    <authorisedRepresentativeName>Biotech Europe Meditech Inc Limited</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>IE-AR-000004696</authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>BIO-HYALUR HV</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-02T19:43:34.010Z</lastUpdated>
  </row>
</eudamedExport>